Skip to main content

Table 4 Adverse events

From: Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study

n (%)

Any grade

Grade 3

Grade 4

Anemia

51 (48%)

0

1 (1%)

Neutropenia

42 (39%)

8 (7%)

1 (1%)

Leukopenia

45 (42%)

0

1 (1%)

Thrombocytopenia

46 (43%)

2 (2%)

1 (1%)

AST increased

49 (46%)

0

0

ALT increased

37 (35%)

1 (1%)

0

Hand-foot syndrome

32 (30%)

2 (2%)

0

Peripheral sensory neuropathy

69 (64%)

10 (9%)

0

Loss of appetite

28 (26%)

3 (3%)

0

General fatigue

25 (23%)

2 (2%)

0

Nausea

26 (24%)

2 (2%)

0

Vomiting

8 (7%)

3 (3%)

0

Diarrhea

19 (18%)

4 (4%)

0

Allergy

6 (3%)

2 (2%)

0